Global Pancreatic Cancer Diagnostic
Global Pancreatic Cancer Diagnostic

Pancreatic Cancer Diagnostic Comprehensive Study by Application (Hospitals, Clinics, Oncology Institutes, Diagnostic Centers), Cancer Type (Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer), Diagnosis (Imaging Tests (CT Scan, MRI, Ultrasound, PET Scan, Angiography and Cholangiopancreatography), Blood Tests (Liver Function Test and Other Blood Tests), Biopsy (Percutaneous Biopsy, Surgical Biopsy and Endoscopic Biopsy), Genetic Counselling and Testing) Players and Region - Global Market Outlook to 2025

Pancreatic Cancer Diagnostic Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Feb 2020 Edition 200 Pages 175 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Pancreatic Cancer Diagnostic Market Definition
According to the American Cancer Society, around 3 percent of all cancers in the United States are pancreatic cancers. Studies conducted by various institutes showed that 91% of pancreatic cancer patients will die within five years of diagnosis and only 9% will survive more than five years. Pancreatic cancer is a type of cancer in which uncontrolled cell growth begins in a part of the pancreas. The pancreas is an organ in a human abdomen that lies behind the lower part of the stomach. It releases enzymes that aid digestion and produces hormones that help to manage blood sugar. Pancreatic cancer is of two types including endocrine pancreatic cancer and exocrine pancreatic cancer. It is occasionally detected at its early stages when it is most curable because it often doesn’t cause symptoms until after it has spread to other organs. The diagnosis of pancreatic cancer done with the help of laboratory tests, imaging tests, biopsy and assessing cancer symptoms. The treatment options for pancreatic cancer are chosen based on the stage of cancer. It involves surgery, chemotherapy, radiation therapy or a combination of these. According to the Hirshberg Foundation for Pancreatic Cancer Research, pancreatic cancer is the 3rd leading cause of cancer-related death in the United States surpassing breast cancer. It is expected to become the 2nd leading cause of cancer-related death in the United States by the year 2021, surpassing colorectal cancer.

The market study is broken down, by Application (Hospitals, Clinics, Oncology Institutes and Diagnostic Centers) and major geographies with country level splits.

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Pancreatic Cancer Diagnostic market throughout the predicted period.

Fujifilm Holdings Corporation (Japan), Roche Holding AG (Switzerland), GE Healthcare (United States), Siemens AG (Germany), Becton, Dickinson and Company (United States), Philips Healthcare (Netherlands), Hitachi Medical Corporation (Japan), Danaher Corporation (United States), Abbott Laboratories (United States) and Canon Medical Systems Corporation (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Myriad Genetics, Inc. (United States), Qiagen (Germany), Asuragen, Inc. (United States), Toshiba Medical Systems Corporation (Japan) and Carestream Health (United States).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Pancreatic Cancer Diagnostic market by Type, Application and Region.

On the basis of geography, the market of Pancreatic Cancer Diagnostic has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Cancer Type, the sub-segment i.e. Endocrine Pancreatic Cancer will boost the Pancreatic Cancer Diagnostic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Imaging Tests (CT Scan, MRI, Ultrasound, PET Scan, Angiography and Cholangiopancreatography) will boost the Pancreatic Cancer Diagnostic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies

In January 2019, Royal Philips, a global leader in health technology, unveiled its latest Imaging Systems range with solutions including the Next MR Wave, Epiq Elite Ultrasound System, DigitalDiagnost C90( Digital X-ray), Intellispace Discovery, Compressed SENSE and Philips IQon (CT) at IRIA 2019, the annual conference of Indian Radiological and Imaging Association, in Chandigarh.


Market Trend
  • Increasing Diagnosed Pancreatic Cancer Cases

Market Drivers
  • Increase in the Prevalence of Pancreatic Cancer
  • Rise in the Cancer Related Deaths Worldwide
  • Increased Consumption of Alcohol and Tobacco Products

Opportunities
  • Development of Healthcare Infrastructure in Emerging Economies
  • Technological Advancements in the Field Of Medical Science
  • Huge Investments and Franchising By Major Players

Restraints
  • Difficulty in Early Diagnosis of the Pancreatic Cancer
  • High Cost of the Cancer Treatments

Challenges
  • Lack of Awareness about Cancer Symptoms among People
  • Low Success Rates of the Clinical Trails


Key Target Audience
Pancreatic Cancer Diagnostic Instrument Manufacturers, Research Organization and Associations, Research Professionals, Emerging Companies, Distributors, Government Body & Associations and End-user

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hospitals
  • Clinics
  • Oncology Institutes
  • Diagnostic Centers
By Cancer Type
  • Endocrine Pancreatic Cancer
  • Exocrine Pancreatic Cancer

By Diagnosis
  • Imaging Tests (CT Scan, MRI, Ultrasound, PET Scan, Angiography and Cholangiopancreatography)
  • Blood Tests (Liver Function Test and Other Blood Tests)
  • Biopsy (Percutaneous Biopsy, Surgical Biopsy and Endoscopic Biopsy)
  • Genetic Counselling and Testing

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Prevalence of Pancreatic Cancer
      • 3.2.2. Rise in the Cancer Related Deaths Worldwide
      • 3.2.3. Increased Consumption of Alcohol and Tobacco Products
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness about Cancer Symptoms among People
      • 3.3.2. Low Success Rates of the Clinical Trails
    • 3.4. Market Trends
      • 3.4.1. Increasing Diagnosed Pancreatic Cancer Cases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pancreatic Cancer Diagnostic, by Application, Cancer Type, Diagnosis and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Pancreatic Cancer Diagnostic (Value)
      • 5.2.1. Global Pancreatic Cancer Diagnostic by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Oncology Institutes
        • 5.2.1.4. Diagnostic Centers
      • 5.2.2. Global Pancreatic Cancer Diagnostic by: Cancer Type (Value)
        • 5.2.2.1. Endocrine Pancreatic Cancer
        • 5.2.2.2. Exocrine Pancreatic Cancer
      • 5.2.3. Global Pancreatic Cancer Diagnostic by: Diagnosis (Value)
        • 5.2.3.1. Imaging Tests (CT Scan, MRI, Ultrasound, PET Scan, Angiography and Cholangiopancreatography)
        • 5.2.3.2. Blood Tests (Liver Function Test and Other Blood Tests)
        • 5.2.3.3. Biopsy (Percutaneous Biopsy, Surgical Biopsy and Endoscopic Biopsy)
        • 5.2.3.4. Genetic Counselling and Testing
      • 5.2.4. Global Pancreatic Cancer Diagnostic Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Pancreatic Cancer Diagnostic: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Fujifilm Holdings Corporation (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Holding AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GE Healthcare (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Siemens AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Becton, Dickinson and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Philips Healthcare (Netherlands)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hitachi Medical Corporation (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Danaher Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abbott Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Canon Medical Systems Corporation (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pancreatic Cancer Diagnostic Sale, by Application, Cancer Type, Diagnosis and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Pancreatic Cancer Diagnostic (Value)
      • 7.2.1. Global Pancreatic Cancer Diagnostic by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Oncology Institutes
        • 7.2.1.4. Diagnostic Centers
      • 7.2.2. Global Pancreatic Cancer Diagnostic by: Cancer Type (Value)
        • 7.2.2.1. Endocrine Pancreatic Cancer
        • 7.2.2.2. Exocrine Pancreatic Cancer
      • 7.2.3. Global Pancreatic Cancer Diagnostic by: Diagnosis (Value)
        • 7.2.3.1. Imaging Tests (CT Scan, MRI, Ultrasound, PET Scan, Angiography and Cholangiopancreatography)
        • 7.2.3.2. Blood Tests (Liver Function Test and Other Blood Tests)
        • 7.2.3.3. Biopsy (Percutaneous Biopsy, Surgical Biopsy and Endoscopic Biopsy)
        • 7.2.3.4. Genetic Counselling and Testing
      • 7.2.4. Global Pancreatic Cancer Diagnostic Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pancreatic Cancer Diagnostic: by Application(USD Million)
  • Table 2. Pancreatic Cancer Diagnostic Hospitals , by Region USD Million (2014-2019)
  • Table 3. Pancreatic Cancer Diagnostic Clinics , by Region USD Million (2014-2019)
  • Table 4. Pancreatic Cancer Diagnostic Oncology Institutes , by Region USD Million (2014-2019)
  • Table 5. Pancreatic Cancer Diagnostic Diagnostic Centers , by Region USD Million (2014-2019)
  • Table 6. Pancreatic Cancer Diagnostic: by Cancer Type(USD Million)
  • Table 7. Pancreatic Cancer Diagnostic Endocrine Pancreatic Cancer , by Region USD Million (2014-2019)
  • Table 8. Pancreatic Cancer Diagnostic Exocrine Pancreatic Cancer , by Region USD Million (2014-2019)
  • Table 9. Pancreatic Cancer Diagnostic: by Diagnosis(USD Million)
  • Table 10. Pancreatic Cancer Diagnostic Imaging Tests (CT Scan, MRI, Ultrasound, PET Scan, Angiography and Cholangiopancreatography) , by Region USD Million (2014-2019)
  • Table 11. Pancreatic Cancer Diagnostic Blood Tests (Liver Function Test and Other Blood Tests) , by Region USD Million (2014-2019)
  • Table 12. Pancreatic Cancer Diagnostic Biopsy (Percutaneous Biopsy, Surgical Biopsy and Endoscopic Biopsy) , by Region USD Million (2014-2019)
  • Table 13. Pancreatic Cancer Diagnostic Genetic Counselling and Testing , by Region USD Million (2014-2019)
  • Table 14. South America Pancreatic Cancer Diagnostic, by Country USD Million (2014-2019)
  • Table 15. South America Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 16. South America Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 17. South America Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 18. Brazil Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 19. Brazil Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 20. Brazil Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 21. Argentina Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 22. Argentina Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 23. Argentina Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 24. Rest of South America Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 25. Rest of South America Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 26. Rest of South America Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 27. Asia Pacific Pancreatic Cancer Diagnostic, by Country USD Million (2014-2019)
  • Table 28. Asia Pacific Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 29. Asia Pacific Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 30. Asia Pacific Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 31. China Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 32. China Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 33. China Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 34. Japan Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 35. Japan Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 36. Japan Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 37. India Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 38. India Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 39. India Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 40. South Korea Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 41. South Korea Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 42. South Korea Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 43. Taiwan Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 44. Taiwan Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 45. Taiwan Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 46. Australia Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 47. Australia Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 48. Australia Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 49. Rest of Asia-Pacific Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 51. Rest of Asia-Pacific Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 52. Europe Pancreatic Cancer Diagnostic, by Country USD Million (2014-2019)
  • Table 53. Europe Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 54. Europe Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 55. Europe Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 56. Germany Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 57. Germany Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 58. Germany Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 59. France Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 60. France Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 61. France Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 62. Italy Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 63. Italy Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 64. Italy Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 65. United Kingdom Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 66. United Kingdom Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 67. United Kingdom Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 68. Netherlands Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 69. Netherlands Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 70. Netherlands Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 71. Rest of Europe Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 72. Rest of Europe Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 73. Rest of Europe Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 74. MEA Pancreatic Cancer Diagnostic, by Country USD Million (2014-2019)
  • Table 75. MEA Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 76. MEA Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 77. MEA Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 78. Middle East Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 79. Middle East Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 80. Middle East Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 81. Africa Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 82. Africa Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 83. Africa Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 84. North America Pancreatic Cancer Diagnostic, by Country USD Million (2014-2019)
  • Table 85. North America Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 86. North America Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 87. North America Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 88. United States Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 89. United States Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 90. United States Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 91. Canada Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 92. Canada Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 93. Canada Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 94. Mexico Pancreatic Cancer Diagnostic, by Application USD Million (2014-2019)
  • Table 95. Mexico Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2014-2019)
  • Table 96. Mexico Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2014-2019)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Pancreatic Cancer Diagnostic: by Application(USD Million)
  • Table 108. Pancreatic Cancer Diagnostic Hospitals , by Region USD Million (2020-2025)
  • Table 109. Pancreatic Cancer Diagnostic Clinics , by Region USD Million (2020-2025)
  • Table 110. Pancreatic Cancer Diagnostic Oncology Institutes , by Region USD Million (2020-2025)
  • Table 111. Pancreatic Cancer Diagnostic Diagnostic Centers , by Region USD Million (2020-2025)
  • Table 112. Pancreatic Cancer Diagnostic: by Cancer Type(USD Million)
  • Table 113. Pancreatic Cancer Diagnostic Endocrine Pancreatic Cancer , by Region USD Million (2020-2025)
  • Table 114. Pancreatic Cancer Diagnostic Exocrine Pancreatic Cancer , by Region USD Million (2020-2025)
  • Table 115. Pancreatic Cancer Diagnostic: by Diagnosis(USD Million)
  • Table 116. Pancreatic Cancer Diagnostic Imaging Tests (CT Scan, MRI, Ultrasound, PET Scan, Angiography and Cholangiopancreatography) , by Region USD Million (2020-2025)
  • Table 117. Pancreatic Cancer Diagnostic Blood Tests (Liver Function Test and Other Blood Tests) , by Region USD Million (2020-2025)
  • Table 118. Pancreatic Cancer Diagnostic Biopsy (Percutaneous Biopsy, Surgical Biopsy and Endoscopic Biopsy) , by Region USD Million (2020-2025)
  • Table 119. Pancreatic Cancer Diagnostic Genetic Counselling and Testing , by Region USD Million (2020-2025)
  • Table 120. South America Pancreatic Cancer Diagnostic, by Country USD Million (2020-2025)
  • Table 121. South America Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 122. South America Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 123. South America Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 124. Brazil Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 125. Brazil Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 126. Brazil Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 127. Argentina Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 128. Argentina Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 129. Argentina Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 130. Rest of South America Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 131. Rest of South America Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 132. Rest of South America Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 133. Asia Pacific Pancreatic Cancer Diagnostic, by Country USD Million (2020-2025)
  • Table 134. Asia Pacific Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 135. Asia Pacific Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 136. Asia Pacific Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 137. China Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 138. China Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 139. China Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 140. Japan Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 141. Japan Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 142. Japan Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 143. India Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 144. India Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 145. India Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 146. South Korea Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 147. South Korea Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 148. South Korea Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 149. Taiwan Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 150. Taiwan Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 151. Taiwan Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 152. Australia Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 153. Australia Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 154. Australia Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 155. Rest of Asia-Pacific Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 156. Rest of Asia-Pacific Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 157. Rest of Asia-Pacific Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 158. Europe Pancreatic Cancer Diagnostic, by Country USD Million (2020-2025)
  • Table 159. Europe Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 160. Europe Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 161. Europe Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 162. Germany Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 163. Germany Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 164. Germany Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 165. France Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 166. France Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 167. France Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 168. Italy Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 169. Italy Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 170. Italy Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 171. United Kingdom Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 172. United Kingdom Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 173. United Kingdom Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 174. Netherlands Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 175. Netherlands Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 176. Netherlands Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 177. Rest of Europe Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 178. Rest of Europe Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 179. Rest of Europe Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 180. MEA Pancreatic Cancer Diagnostic, by Country USD Million (2020-2025)
  • Table 181. MEA Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 182. MEA Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 183. MEA Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 184. Middle East Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 185. Middle East Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 186. Middle East Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 187. Africa Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 188. Africa Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 189. Africa Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 190. North America Pancreatic Cancer Diagnostic, by Country USD Million (2020-2025)
  • Table 191. North America Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 192. North America Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 193. North America Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 194. United States Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 195. United States Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 196. United States Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 197. Canada Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 198. Canada Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 199. Canada Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 200. Mexico Pancreatic Cancer Diagnostic, by Application USD Million (2020-2025)
  • Table 201. Mexico Pancreatic Cancer Diagnostic, by Cancer Type USD Million (2020-2025)
  • Table 202. Mexico Pancreatic Cancer Diagnostic, by Diagnosis USD Million (2020-2025)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pancreatic Cancer Diagnostic: by Application USD Million (2014-2019)
  • Figure 5. Global Pancreatic Cancer Diagnostic: by Cancer Type USD Million (2014-2019)
  • Figure 6. Global Pancreatic Cancer Diagnostic: by Diagnosis USD Million (2014-2019)
  • Figure 7. South America Pancreatic Cancer Diagnostic Share (%), by Country
  • Figure 8. Asia Pacific Pancreatic Cancer Diagnostic Share (%), by Country
  • Figure 9. Europe Pancreatic Cancer Diagnostic Share (%), by Country
  • Figure 10. MEA Pancreatic Cancer Diagnostic Share (%), by Country
  • Figure 11. North America Pancreatic Cancer Diagnostic Share (%), by Country
  • Figure 12. Global Pancreatic Cancer Diagnostic share by Players 2019 (%)
  • Figure 13. Global Pancreatic Cancer Diagnostic share by Players (Top 3) 2019(%)
  • Figure 14. Global Pancreatic Cancer Diagnostic share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Fujifilm Holdings Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 17. Fujifilm Holdings Corporation (Japan) Revenue: by Geography 2019
  • Figure 18. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Roche Holding AG (Switzerland) Revenue: by Geography 2019
  • Figure 20. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 21. GE Healthcare (United States) Revenue: by Geography 2019
  • Figure 22. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Siemens AG (Germany) Revenue: by Geography 2019
  • Figure 24. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 25. Becton, Dickinson and Company (United States) Revenue: by Geography 2019
  • Figure 26. Philips Healthcare (Netherlands) Revenue, Net Income and Gross profit
  • Figure 27. Philips Healthcare (Netherlands) Revenue: by Geography 2019
  • Figure 28. Hitachi Medical Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Hitachi Medical Corporation (Japan) Revenue: by Geography 2019
  • Figure 30. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 31. Danaher Corporation (United States) Revenue: by Geography 2019
  • Figure 32. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 33. Abbott Laboratories (United States) Revenue: by Geography 2019
  • Figure 34. Canon Medical Systems Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Canon Medical Systems Corporation (Japan) Revenue: by Geography 2019
  • Figure 36. Global Pancreatic Cancer Diagnostic: by Application USD Million (2020-2025)
  • Figure 37. Global Pancreatic Cancer Diagnostic: by Cancer Type USD Million (2020-2025)
  • Figure 38. Global Pancreatic Cancer Diagnostic: by Diagnosis USD Million (2020-2025)
  • Figure 39. South America Pancreatic Cancer Diagnostic Share (%), by Country
  • Figure 40. Asia Pacific Pancreatic Cancer Diagnostic Share (%), by Country
  • Figure 41. Europe Pancreatic Cancer Diagnostic Share (%), by Country
  • Figure 42. MEA Pancreatic Cancer Diagnostic Share (%), by Country
  • Figure 43. North America Pancreatic Cancer Diagnostic Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Fujifilm Holdings Corporation (Japan)
  • Roche Holding AG (Switzerland)
  • GE Healthcare (United States)
  • Siemens AG (Germany)
  • Becton, Dickinson and Company (United States)
  • Philips Healthcare (Netherlands)
  • Hitachi Medical Corporation (Japan)
  • Danaher Corporation (United States)
  • Abbott Laboratories (United States)
  • Canon Medical Systems Corporation (Japan)
Additional players considered in the study are as follows:
Myriad Genetics, Inc. (United States) , Qiagen (Germany) , Asuragen, Inc. (United States) , Toshiba Medical Systems Corporation (Japan) , Carestream Health (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation